Characteristic | Value |
---|---|
Number of eyes/patients | 23 eyes/20 patients |
Sex, n (%) | |
Male | 13 (65%) |
Female | 7 (35%) |
Age (years) | |
Range | 35–82 |
Mean±SD | 62±10 |
Type of diabetes, n (%) | |
Type 1 | 1 (5%) |
Type 2 | 19 (95%) |
Duration of diabetes (years) | |
Range | 1–27 |
Mean±SD | 12±8 |
HbA1c (%) | |
Range | 6.0–11.0 |
Mean±SD | 7.2±1.4 |
Type of CSMO, n (%) | |
Focal | 5 (22%) |
Diffuse | 18 (78%) |
Type of diabetic retinopathy, n (%) | |
Background | 15 (65%) |
Proliferative | 8 (35%) |
CRT (µm) | |
Mean±SD | 484±117 |
Range | 401–798 |
BCVA | |
Mean±SD in ETDRS letters (Snellen eq.) | 44±20 (20/160) |
Range in Snellen equivalent | CF—20/30 |
Previous treatments, n (%) | |
Anti-VEGF (bevacizumab) | 11 (48%) |
Focal Laser | 6 (26%) |
Intravitreal Steroids | 2 (8%) |
Anti-VEGF (bevacizumab) + focal laser | 4 (17%) |
PRP | 8 (35%) |
BCVA, best-corrected visual acuity; CF, count fingers; CRT, central retinal thickness; CSME, clinically significant macular oedema; ETDRS, Early Treatment Diabetic Retinopathy Study; PRP, panretinal photocoagulation; VEGF, vascular endothelial grow factor.